PE20061148A1 - Sal potasica de n-(4-fluorobencil)-5-hidroxi-1-metil-2-(1-metil-1-{[(5-metil-1,3,4-oxadiazol-2-il)carbonil]amino}etil)-6-oxo-1,6-dihidropirimidin-4-carboxamida - Google Patents

Sal potasica de n-(4-fluorobencil)-5-hidroxi-1-metil-2-(1-metil-1-{[(5-metil-1,3,4-oxadiazol-2-il)carbonil]amino}etil)-6-oxo-1,6-dihidropirimidin-4-carboxamida

Info

Publication number
PE20061148A1
PE20061148A1 PE2005001398A PE2005001398A PE20061148A1 PE 20061148 A1 PE20061148 A1 PE 20061148A1 PE 2005001398 A PE2005001398 A PE 2005001398A PE 2005001398 A PE2005001398 A PE 2005001398A PE 20061148 A1 PE20061148 A1 PE 20061148A1
Authority
PE
Peru
Prior art keywords
methyl
potassium salt
dihydropyrimidin
fluorobenzyl
oxadiazol
Prior art date
Application number
PE2005001398A
Other languages
English (en)
Inventor
Kevin M Belyk
Vincenzo Summa
Philip Jones
Henry G Morrison
Original Assignee
Merck & Co Inc
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc, Angeletti P Ist Richerche Bio filed Critical Merck & Co Inc
Publication of PE20061148A1 publication Critical patent/PE20061148A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA SAL POTASICA CRISTALINA DEL COMPUESTO (A) QUE ES N-(4-FLUOROBENCIL)-5-HIDROXI-1-METIL-2-(1-METIL-1-{[(5-METIL-1,3,4-OXADIAZOL-2-IL)CARBONIL]AMINO}ETIL)-6-OXO-1,6-DIHIDROPIRIMIDIN-4-CARBOXAMIDA, ENTRE OTROS; CUYA SAL POTASICA CRISTALINA ANHIDRA TIENE UN PATRON DE DIFRACCION DE CRISTALES FINOS POR RAYOS X OBTENIDO USANDO LA RADIACION DEL COBRE Ka QUE COMPRENDE VALORES DE 2 TETA EN GRADOS DE 5,9; 12,5; 20,0; 20,6 Y 25,6. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA INTEGRASA DEL VIRUS VIH SIENDO UTILES EN EL TRATAMIENTO DEL SIDA
PE2005001398A 2004-12-03 2005-12-01 Sal potasica de n-(4-fluorobencil)-5-hidroxi-1-metil-2-(1-metil-1-{[(5-metil-1,3,4-oxadiazol-2-il)carbonil]amino}etil)-6-oxo-1,6-dihidropirimidin-4-carboxamida PE20061148A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03

Publications (1)

Publication Number Publication Date
PE20061148A1 true PE20061148A1 (es) 2006-11-09

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001398A PE20061148A1 (es) 2004-12-03 2005-12-01 Sal potasica de n-(4-fluorobencil)-5-hidroxi-1-metil-2-(1-metil-1-{[(5-metil-1,3,4-oxadiazol-2-il)carbonil]amino}etil)-6-oxo-1,6-dihidropirimidin-4-carboxamida

Country Status (36)

Country Link
US (2) US7754731B2 (es)
EP (2) EP1819683B1 (es)
JP (1) JP4705956B2 (es)
KR (2) KR20130122031A (es)
CN (1) CN101068793B (es)
AR (2) AR052034A1 (es)
AT (2) ATE534645T1 (es)
AU (1) AU2005311671B8 (es)
BR (1) BRPI0518760A8 (es)
CA (1) CA2588398C (es)
CR (1) CR9146A (es)
CY (1) CY1112859T1 (es)
DK (1) DK1819700T3 (es)
EA (1) EA012418B1 (es)
ES (2) ES2375788T3 (es)
GE (1) GEP20105086B (es)
HK (1) HK1115011A1 (es)
HR (1) HRP20120066T1 (es)
IL (1) IL183614A (es)
MA (1) MA29120B1 (es)
ME (1) ME01985B (es)
MX (1) MX2007006639A (es)
MY (1) MY144320A (es)
NI (1) NI200700138A (es)
NO (1) NO338784B1 (es)
NZ (1) NZ555376A (es)
PE (1) PE20061148A1 (es)
PL (1) PL1819700T3 (es)
PT (1) PT1819700E (es)
RS (1) RS52197B (es)
SI (1) SI1819700T1 (es)
TN (1) TNSN07215A1 (es)
TW (1) TWI344463B (es)
UA (1) UA87884C2 (es)
WO (2) WO2006060730A2 (es)
ZA (1) ZA200704130B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272827A1 (en) 2004-03-11 2011-01-12 4Sc Ag Sulphonylpyrroles as hdac inhibitors
EP1904067B2 (en) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
AU2005311672B2 (en) * 2004-12-03 2010-07-22 Merck Sharp & Dohme Corp. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
ES2727577T3 (es) * 2004-12-03 2019-10-17 Merck Sharp & Dohme Composición farmacéutica que contiene un agente antinucleante
CN101453986A (zh) * 2006-03-14 2009-06-10 默克公司 通过微研磨和在微晶种上结晶生产结晶有机微粒组合物的方法和设备及其应用
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
CA2702317A1 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Novel pyrimidinecarboxamide derivatives
CN103254138A (zh) * 2008-01-08 2013-08-21 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
ES2549387T3 (es) * 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
US8703801B2 (en) * 2009-12-07 2014-04-22 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
US8987272B2 (en) * 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
JP5889275B2 (ja) * 2010-04-01 2016-03-22 テバ ファーマシューティカル インダストリーズ リミティド ラルテグラビル塩およびその結晶形
US8962833B2 (en) 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012137142A1 (en) 2011-04-06 2012-10-11 Lupin Limited Novel salts of raltegravir
EP2699094A4 (en) * 2011-04-22 2014-12-17 Merck Sharp & Dohme TASTE-MASKED FORMULATIONS BY RALTEGRAVIR
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) * 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
EP2529741B1 (en) 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
WO2013037731A1 (de) 2011-09-16 2013-03-21 Hexal Ag Neue polymorphe form von raltegravir-kalium
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
WO2013098854A2 (en) * 2011-12-26 2013-07-04 Emcure Pharmaceuticals Limited Synthesis of raltegravir
CA2863575A1 (en) 2012-01-25 2013-08-01 Lupin Limited Stable amorphous raltegravir potassium premix and process for the preparation thereof
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
US9856270B2 (en) 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
US20170253585A1 (en) 2014-02-03 2017-09-07 Mylan Laboratories Ltd. Processes for the preparation of intermediates of raltegravir
WO2015140765A1 (en) * 2014-03-21 2015-09-24 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
US10259778B2 (en) 2014-11-10 2019-04-16 Aurobindo Pharma Ltd Process for the preparation of raltegravir
EP3472134B1 (en) 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
US10752618B2 (en) * 2016-09-15 2020-08-25 Lupin Limited Process for the preparation of pure and stable crystalline Raltegravir potassium form 3
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
HRP20220613T1 (hr) 2017-11-14 2022-06-24 Cambrex Profarmaco Milano S.R.L. Postupak priprave raltegavira
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (es) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5717097A (en) * 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
CZ20012160A3 (cs) * 1998-12-25 2001-10-17 Shionogi & Co., Ltd. Heteroaromatické deriváty s inhibiční aktivitou proti HIV integráze
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
CA2425440C (en) 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
GB0028483D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
CN102219750B (zh) * 2001-10-26 2013-05-29 P.安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
EP1465889B1 (en) * 2001-12-21 2017-03-22 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TR200401663T1 (tr) * 2002-11-20 2005-04-21 Japan Tobacco Inc. 4-oksokuinolin bileşiği ve bunun HIV integraz inhibitörü olarak kullanımı.
JP4733986B2 (ja) * 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP1904067B2 (en) 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
AU2005311672B2 (en) 2004-12-03 2010-07-22 Merck Sharp & Dohme Corp. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
ES2727577T3 (es) 2004-12-03 2019-10-17 Merck Sharp & Dohme Composición farmacéutica que contiene un agente antinucleante

Also Published As

Publication number Publication date
CY1112859T1 (el) 2016-04-13
AR101429A2 (es) 2016-12-21
CA2588398A1 (en) 2006-06-08
CN101068793A (zh) 2007-11-07
PL1819700T3 (pl) 2012-04-30
JP4705956B2 (ja) 2011-06-22
US20100249410A1 (en) 2010-09-30
HK1115011A1 (en) 2008-11-14
JP2008521933A (ja) 2008-06-26
AR052034A1 (es) 2007-02-28
ME01985B (me) 2012-10-31
ES2375788T3 (es) 2012-03-06
US7754731B2 (en) 2010-07-13
CN101068793B (zh) 2011-05-25
ATE534645T1 (de) 2011-12-15
IL183614A0 (en) 2007-09-20
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
BRPI0518760A2 (pt) 2008-12-09
EP1819700B1 (en) 2011-11-23
KR20070089990A (ko) 2007-09-04
US20060122205A1 (en) 2006-06-08
ES2370136T3 (es) 2011-12-13
WO2006060730A3 (en) 2006-08-17
TWI344463B (en) 2011-07-01
TNSN07215A1 (en) 2008-11-21
AU2005311671B2 (en) 2011-01-27
US8357798B2 (en) 2013-01-22
GEP20105086B (en) 2010-10-11
EA200701204A1 (ru) 2007-12-28
NZ555376A (en) 2009-11-27
NO338784B1 (no) 2016-10-17
AU2005311671A1 (en) 2006-06-08
NO20073404L (no) 2007-07-02
WO2006060730A2 (en) 2006-06-08
WO2006060712A3 (en) 2006-09-21
WO2006060712A2 (en) 2006-06-08
RS52197B (en) 2012-10-31
ATE518844T1 (de) 2011-08-15
TW200631944A (en) 2006-09-16
WO2006060712A9 (en) 2006-07-27
EA012418B1 (ru) 2009-10-30
UA87884C2 (uk) 2009-08-25
SI1819700T1 (sl) 2012-07-31
IL183614A (en) 2012-03-29
DK1819700T3 (da) 2012-03-19
KR101350420B1 (ko) 2014-02-17
CA2588398C (en) 2011-07-12
AU2005311671B8 (en) 2011-02-10
MX2007006639A (es) 2007-06-19
KR20130122031A (ko) 2013-11-06
BRPI0518760A8 (pt) 2017-12-12
EP1819700A2 (en) 2007-08-22
EP1819683B1 (en) 2011-08-03
EP1819683A2 (en) 2007-08-22
ZA200704130B (en) 2008-08-27
HRP20120066T1 (hr) 2012-03-31
CR9146A (es) 2007-10-04
MY144320A (en) 2011-08-29
MA29120B1 (fr) 2007-12-03

Similar Documents

Publication Publication Date Title
PE20061148A1 (es) Sal potasica de n-(4-fluorobencil)-5-hidroxi-1-metil-2-(1-metil-1-{[(5-metil-1,3,4-oxadiazol-2-il)carbonil]amino}etil)-6-oxo-1,6-dihidropirimidin-4-carboxamida
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
AR037996A1 (es) Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
ATE517874T1 (de) Pyrimidinone als modulatoren von caseinkinase ii (ck2)
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
UY32149A (es) Formulaciones de glifosato que contienen agentes tensioactivos de amidoalquilaminas
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
PE20060372A1 (es) Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
CY1109168T1 (el) Συνθεση νατριουχου φονταπαρινοξης υψηλης καθαροτητας
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse

Legal Events

Date Code Title Description
FC Refusal